risdiplam
Selected indexed studies
- Risdiplam: A Review in Spinal Muscular Atrophy. (CNS Drugs, 2022) [PMID:35284988]
- Risdiplam in Type 1 Spinal Muscular Atrophy. (N Engl J Med, 2021) [PMID:33626251]
- Risdiplam. (, 2012) [PMID:39401307]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Risdiplam: A Review in Spinal Muscular Atrophy. (2022) pubmed
- Risdiplam in Type 1 Spinal Muscular Atrophy. (2021) pubmed
- Risdiplam. (2012) pubmed
- Risdiplam in Presymptomatic Spinal Muscular Atrophy. (2025) pubmed
- How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. (2022) pubmed
- Risdiplam: First Approval. (2020) pubmed
- Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). (2023) pubmed
- Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy. (2025) pubmed
- Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. (2022) pubmed
- Risdiplam for spinal muscular atrophy. (2022) pubmed